Sign up
Pharma Capital

OptiBiotix Health 'in the strongest position they've ever been'

Stephen O'Hara, chief executive of OptiBiotix Health plc (LON:OPTI) tells Proactive's Andrew Scott the big focus for them now is on the commercialisation of their technology across the company's platforms.

''2018 has started off very, very well'', O'Hara says.

He mentions they'll be presenting next week at ProBiota in Barcelona - a leading conference attended by the movers and shakers of the industry.

The poster and verbal exposition will focus on OptiBiotix's ability to identify and develop targeted prebiotics which can enhance the growth rate and health benefits of specific microbial species. In doing so they aid the efficacy of probiotic products.

''We've got a lot going on and a lot of relationships with partners that we haven't announced but are close to formalising deals on''.


View full OPTI profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.